MISGAV, Israel & LONDON--(BUSINESS WIRE)--Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company developing the ‘biopump’ sustained-action protein therapy for the treatment of chronic diseases, has completed its move to a new facility on the Teradion Business Park in Misgav, Israel. The new facility brings together Medgenics’ corporate operations with larger R&D laboratories on one site.
